CIK 0001395937 · Large accelerated filer
Syndax Pharmaceuticals Inc
Sign in to watch- Ticker
- SNDX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 320162505
- Phone
- 781-419-1400
- Business address
- 730 THIRD AVENUE, 9TH FLOOR, NEW YORK, NY, 10017
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $113,716
- in 1 filing, $114K under 10b5-1 plans
Net −$113,716. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-10-29 | Podlesak Dennis Director | Sale 10b5-1 | −8,000 | $14.21 | $114K | 239,763 |
| 2026-07-08 | Metzger Michael A Chief Executive Officer | Sale 10b5-1 | −32,375 | $24.24 | $785K | 484,843 |
| 2026-06-12 | Botwood Nicholas A.J. Head of R&D, CMO | Sale 10b5-1 | −31,235 | $18.14 | $567K | 60,885 |
| 2026-06-11 | Botwood Nicholas A.J. Head of R&D, CMO | Sale 10b5-1 | −34,280 | $18.00 | $617K | 60,885 |
| 2026-06-01 | Goldan Keith A. Chief Financial Officer | Sale | −1,177 | $18.99 | $22K | 139,252 |
| 2026-06-01 | Metzger Michael A Chief Executive Officer | Sale | −6,847 | $18.99 | $130K | 484,843 |
| 2026-02-09 | Metzger Michael A Chief Executive Officer | Sale | −17,159 | $21.03 | $361K | 491,690 |
| 2026-02-09 | Goldan Keith A. Chief Financial Officer | Sale | −3,410 | $21.03 | $72K | 140,429 |
| 2026-02-06 | Metzger Michael A Chief Executive Officer | Sale | −7,412 | $20.62 | $153K | 508,849 |
| 2026-02-06 | Goldan Keith A. Chief Financial Officer | Sale | −2,082 | $20.62 | $43K | 143,839 |
| 2025-09-08 | Metzger Michael A Chief Executive Officer | Sale 10b5-1 | −157,307 | $16.41 | $2.6M | 298,661 |
| 2025-08-18 | Podlesak Dennis Director | Sale 10b5-1 | −19,200 | $15.84 | $304K | 191,763 |
| 2025-08-15 | Podlesak Dennis Director | Sale 10b5-1 | −19,200 | $15.54 | $298K | 191,763 |
| 2025-08-14 | Podlesak Dennis Director | Sale 10b5-1 | −19,200 | $14.19 | $273K | 191,763 |
| 2025-07-16 | Goldan Keith A. Chief Financial Officer | Sale | −1,296 | $9.29 | $12K | 92,450 |
| 2025-07-16 | Metzger Michael A Chief Executive Officer | Sale | −7,534 | $9.29 | $70K | 298,661 |
| 2025-03-04 | Metzger Michael A Chief Executive Officer | Sale 10b5-1 | −7,814 | $15.05 | $118K | 300,121 |
| 2025-02-10 | Goldan Keith A. Chief Financial Officer | Sale | −3,777 | $15.50 | $59K | 90,746 |
| 2025-02-10 | Metzger Michael A Chief Executive Officer | Sale | −13,288 | $15.50 | $206K | 300,121 |
| 2025-02-10 | Gallagher Neil President, Head of R&D | Sale | −4,618 | $15.50 | $72K | 85,095 |
Page 1 of 4 · 77 trades